Management of Hyperthyroidism‑Induced Cardiac Remodeling

Immediate Pharmacologic Management

Start a β‑blocker promptly in all hyperthyroid patients to lower heart rate to near‑normal, thereby reducing tachycardia‑mediated ventricular dysfunction. (American Heart Association) 1
Target heart rate near normal to improve the tachycardia‑mediated component of cardiac dysfunction while direct thyroid‑hormone inotropic effects are still present. (American Heart Association) 2
β‑Blockers rapidly improve cardiac symptoms and are essential for preventing cardiovascular complications, the leading cause of death in patients > 50 years with hyperthyroidism. (American Heart Association) 3
If β‑blockers are contraindicated, use non‑dihydropyridine calcium‑channel blockers (diltiazem or verapamil) for rate control. (American College of Cardiology; European Society of Cardiology) 4
Reserve digoxin for severe left‑ventricular dysfunction with hemodynamic instability, as its efficacy is reduced when adrenergic tone is high. (American College of Cardiology) 4

Hyperthyroidism produces marked hemodynamic changes: ↓ systemic vascular resistance, ↑ preload (≈ 25 % rise in blood volume), ↓ afterload, and cardiac output that can rise up to 300 % of baseline. (American Heart Association) 6
Triiodothyronine (T3) exerts a direct, reversible functional cardiomyopathy independent of β‑adrenergic activation. (American Heart Association) 7
Pulmonary hypertension may develop, leading to right‑ventricular dilation and elevated right‑atrial pressures. (American Heart Association) 8
Persistent sinus tachycardia or rapid ventricular rates from atrial fibrillation/flutter constitute the tachycardia‑induced component responsible for most cardiac dysfunction in severe, long‑standing hyperthyroidism. (American Heart Association) 7

Achieving a euthyroid state is essential; anti‑arrhythmic drugs and cardioversion are generally ineffective while thyrotoxicosis persists. (American College of Cardiology; European Society of Cardiology) 4
Cardiac remodeling and dysfunction are reversible once thyroid function normalizes. (American Heart Association) 1
Definitive therapies aimed at rapid thyroid normalization include methimazole (preferred antithyroid drug), radioactive iodine, and thyroidectomy. (European Society of Cardiology) 5

Patients > 50 years have cardiovascular complications as the primary cause of mortality after hyperthyroidism treatment. (American Heart Association) 1
Coexisting cardiac disease (ischemic, hypertensive, or valvular) amplifies the hyperthyroid workload, increasing the risk of heart failure. (American Heart Association) 7
Severe, long‑standing hyperthyroidism can present with reduced contractility, low cardiac output, and overt heart‑failure signs. (American Heart Association) 7

Atrial fibrillation occurs in 10–25 % of hyperthyroid patients, especially elderly males. (European Society of Cardiology) 5
Anticoagulation should be guided by the CHA₂DS₂‑VASc score rather than thyroid status alone. (American College of Cardiology) 4
AF often converts spontaneously to sinus rhythm after restoration of euthyroidism. (American College of Cardiology; European Society of Cardiology) 4
Defer cardioversion until the patient is euthyroid; success rates are poor during active thyrotoxicosis. (American College of Cardiology; European Society of Cardiology) 4

Prompt recognition and effective management of cardiac manifestations are critical to prevent mortality. (American Heart Association) 1
Monitor for improvement in cardiac symptoms and function as thyroid hormone levels normalize. (American Heart Association) 3
Re‑evaluate cardiac structure and function after achieving euthyroidism to confirm reversal of remodeling. (American Heart Association) 2
Cardiac dysfunction typically improves substantially once excess thyroid hormone is controlled. (American Heart Association) 1